Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J McIntyre

Showing results (421-430 of 438) with videos related to

Pageof 44
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
Pain Medicine (Malden, Mass.)|February 24, 2018
An Integrated Quantitative Index for Measuring Chronic Multisite Pain: The Multiple Areas of Pain (MAP) StudyMark S Wallace, James North, Eric J Grigsby, et al.
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Journal of Medicinal Chemistry|December 16, 1997
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamideH G Selnick, N J Liverton, J J Baldwin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
The pseudo-caspase FLIP(L) regulates cell fate following p53 activationAndrea Lees, Alexander J McIntyre, Nyree T Crawford, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Ebiomedicine|November 7, 2025
Genetic diagnostic yield by MRI pattern in children with cerebral palsy: a population-based studyJesia G Berry, Ajay Taranath, Robert Goetti, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Pageof 44

Showing results (421-430 of 438) with videos related to

Sort By:
Pageof 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.
Pain Medicine (Malden, Mass.)|February 24, 2018
An Integrated Quantitative Index for Measuring Chronic Multisite Pain: The Multiple Areas of Pain (MAP) StudyMark S Wallace, James North, Eric J Grigsby, et al.
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Journal of Medicinal Chemistry|December 16, 1997
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamideH G Selnick, N J Liverton, J J Baldwin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma ExposureMichael T Rudd, John A McCauley, John W Butcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
The pseudo-caspase FLIP(L) regulates cell fate following p53 activationAndrea Lees, Alexander J McIntyre, Nyree T Crawford, et al.
Journal of Medicinal Chemistry|February 19, 2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitorJohn A McCauley, Charles J McIntyre, Michael T Rudd, et al.
Ebiomedicine|November 7, 2025
Genetic diagnostic yield by MRI pattern in children with cerebral palsy: a population-based studyJesia G Berry, Ajay Taranath, Robert Goetti, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Pageof 44